Frontiers in Immunology (May 2022)

Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status

  • Kazuki M. Matsuda,
  • Ayumi Yoshizaki,
  • Kei Yamaguchi,
  • Kei Yamaguchi,
  • Eriko Fukuda,
  • Taishi Okumura,
  • Taishi Okumura,
  • Koji Ogawa,
  • Koji Ogawa,
  • Chihiro Ono,
  • Chihiro Ono,
  • Yuta Norimatsu,
  • Hirohito Kotani,
  • Teruyoshi Hisamoto,
  • Ruriko Kawanabe,
  • Ai Kuzumi,
  • Takemichi Fukasawa,
  • Satoshi Ebata,
  • Takuya Miyagawa,
  • Asako Yoshizaki-Ogawa,
  • Naoki Goshima,
  • Naoki Goshima,
  • Shinichi Sato

DOI
https://doi.org/10.3389/fimmu.2022.893086
Journal volume & issue
Vol. 13

Abstract

Read online

Autoantibodies are found in various pathological conditions such as autoimmune diseases, infectious diseases, and malignant tumors. However their clinical implications have not yet been fully elucidated. Herein, we conducted proteome-wide autoantibody screening and quantification with wet protein arrays consisting of proteins synthesized from proteome-wide human cDNA library (HuPEX) maintaining their three-dimensional structure. A total of 565 autoantibodies were identified from the sera of three representative inflammatory disorders (systemic sclerosis, psoriasis, and cutaneous arteritis). Each autoantibody level either positively or negatively correlated with serum levels of C-reactive protein, the best-recognized indicator of inflammation. In particular, we discovered total levels of a subset of autoantibodies correlates with the severity of clinical symptoms. From the sera of malignant melanoma, 488 autoantibodies were detected. Notably, patients with metastases had increased overall autoantibody production compared to those with tumors limiting to the primary site. Collectively, proteome-wide screening of autoantibodies using the in vitro proteome can reveal the “autoantibody landscape” of human subjects and may provide novel clinical biomarkers.

Keywords